CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 21,594	$ 24,822
Operating costs and expenses:
Cost of goods sold	7,060	5,315
Research and development	30,469	107,253
General and administrative	21,081	27,339
Restructuring, impairment and costs of terminated program	21,193	1,475
Impairment of goodwill	76,501	0
Total operating costs and expenses	156,304	141,382
Loss from operations	(134,710)	(116,560)
Non-operating income (expense):
Change in fair value of development derivative liability	0	33,427
Non-cash interest expense on liabilities related to the sales of future royalties	(6,405)	(7,529)
Interest income and other income (expense), net	4,034	395
Total non-operating income (expense), net	(2,371)	26,293
Loss before provision for income taxes	(137,081)	(90,267)
Provision (benefit) for income taxes	(63)	126
Net loss	$ (137,018)	$ (90,393)
Basic net loss per share (in dollars per share)	$ (0.73)	$ (0.49)
Diluted net loss per share (in dollars per share)	$ (0.73)	$ (0.49)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	188,875	185,848
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	188,875	185,848
Product sales
Revenue:
Total revenue	$ 4,718	$ 5,688
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	16,861	17,561
License, collaboration and other revenue
Revenue:
Total revenue	$ 15	$ 1,573